scholarly journals Longitudinal Modeling of Informatively Censored Patient-Reported Outcomes Data in Oncology: Application to a Phase Iii Clinical Trial of Non-Small Cell Lung Cancer

2016 ◽  
Vol 19 (3) ◽  
pp. A158-A159
Author(s):  
K Houghton ◽  
M Boye ◽  
L Bowman ◽  
J Brown ◽  
D Stull
Keyword(s):  
Lung Cancer ◽  
Clinical Trial ◽  
Small Cell Lung Cancer ◽  
Patient Reported Outcomes ◽  
Small Cell ◽  
Phase Iii ◽  
Longitudinal Modeling ◽  
Small Cell Lung ◽  
Phase Iii Clinical Trial ◽  
Patient Reported

scholarly journals Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer

2021 ◽  
Vol 17 (10) ◽  
pp. 1165-1184
Author(s):  
Marina C Garassino ◽  
Luis Paz-Ares ◽  
Rina Hui ◽  
Corinne Faivre-Finn ◽  
Alex Spira ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Patient Reported Outcomes ◽  
Small Cell ◽  
Phase Iii ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Unresectable Stage ◽  
Patient Reported

Aim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus placebo after CRT in patients with unresectable, stage III non-small-cell lung cancer. If available, pre-CRT tumor tissue was tested for PD-L1 tumor-cell expression, scored at prespecified (25%) and post-hoc (1%) cut-offs. PROs were assessed using EORTC QLQ C30/-LC13. Results: Similar to the intent-to-treat (ITT) population, most PROs remained stable over time across PD-L1 and CRT subgroups, with few clinically relevant differences between treatment arms. Time to deterioration was generally similar to the ITT population. Conclusion: Neither PD-L1 expression nor prior CRT-related variables influenced PROs with durvalumab therapy. Clinical trial registration: NCT02125461 (ClinicalTrials.gov)

RANIDO: A phase III clinical trial of racotumomab-alum or nimotuzumab versus docetaxel in advanced non-small cell lung cancer patients.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. TPS3111-TPS3111
Author(s):  
Maurenis Hernandez ◽  
Eduardo Rafael Santiesteban ◽  
Ramon Alberto Ortiz ◽  
Elia Neninger ◽  
Soraida Acosta ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trial ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Phase Iii Clinical Trial ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document